/PRNewswire/ Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), announced today that.
AHN Cancer Institute Recruits Top Physician-Researchers from UPMC For High Level Roles prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Allegheny Health Network Improves Cancer Patients Experience and Comfort with Virtual Reality Technology Pioneered by Harvard MedTech prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
AHN Cancer Institute Becomes One of Nation’s First to Use Breakthrough Technology to Advance Radiation Therapy
Share Article
Allegheny Health Network (AHN) Cancer Institute is one of just six U.S. health systems, and the first in western Pennsylvania, to begin treating cancer patients with the Elekta Unity MR-Linac, an innovative first-of-its-kind technology that combines diagnostic quality Magnetic Resonance Imaging (MRI) and linear accelerator radiotherapy in one interactive machine to more accurately and safely eradicate malignant tumors.
The Elekta Unity MR-Linac at AHN Allegheny General Hospital
“The MR-Linac will enable us to deliver higher doses of radiation to cancerous tumors more accurately and safely.and is also uniquely suited to the treatment of tumors that cannot be treated with standard technologies. Tom Colonias, MD, Director of Thoracic Malignancies, AHN Cancer Institute
Allegheny Health Network Offers T-VEC Virus-Based Treatment for Advanced Melanoma
Share Article
Pittsburgh-based Allegheny Health Network is offering patients with advanced melanoma treatment with an oncolytic (cancer-killing) virus called Imlygic or T-VEC. It is injected directly into the tumor, where it works by replicating inside the cancer cells.
AHN surgical oncologist Howard Edington, MD, talks with patient Paul Kirsch prior to treatment with T-VEC
“Unlike other therapies for advanced melanoma, T-VEC is usually well tolerated and is suitable for many patients, including the elderly. It also has a “bystander effect,” killing nearby tiny lesions in addition to the primary tumor.” - Howard Edington, MD, AHN surgical oncologist